Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots

• US 20080050389A1
• Filed: 12/18/2006
• Published: 02/28/2008
• Est. Priority Date: 05/21/1998
• Status: Active Grant

• Current Assignee: Abd Higazi, Douglas Cines, Juan Murciano, Ronald Taylor, Vladimir Muzykantov
• Original Assignee: Abd Higazi, Douglas Cines, Juan Murciano, Ronald Taylor, Vladimir Muzykantov
• Inventors: Higazi, Abd, Taylor, Ronald, Murciano, Juan, Cines, Douglas, Muzykantov, Vladimir
• Granted Patent: US 7,837,997 B2
• Time in Patent Office: Days
• US Class Current: 424/153.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/18 Erythrocytes haemoglobin A61K38/42
• CPC Class Codes: A61K 38/166 Streptokinase
• CPC Class Codes: A61K 38/177 Receptors; Cell surface antigens; Cell surface determinants
• CPC Class Codes: A61K 38/49 Urokinase; Tissue plasminogen activator
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.

Claims

1. A composition comprising a fibrinolytic or anticoagulant drug biocompatibly coupled to a red blood cell carrier.

6. A method for decreasing the rate of elimination of a fibrinolytic or anticoagulant drug from the bloodstream of an animal and decreasing deposition of the drug in tissues of the animal comprising administering to the animal a composition of claim 1.

7. A method for increasing degradation of existing fibrin clots in blood of an animal comprising administering to an animal a composition of claim 1.

8. A method of preventing and treating uncontrolled formation of intravascular clots in an animal comprising administering to an animal suffering from uncontrolled formation of intravascular clots a composition of claim 1.

2. A composition comprising biotinylated plasminogen activator or biotinylated receptor for plasminogen activator precursor cross-linked monovalently to a biotinylated red blood cell carrier via streptavidin.

3. A composition comprising biotinylated plasminogen activator or biotinylated receptor for plasminogen activator precursor conjugated with a biotinylated monoclonal antibody specific for red blood cells via streptavidin.

4. The composition of claim 3 wherein the monoclonal antibody is against human CR1.

5. A method for minimizing potential hazardous interactions of urokinase with endothelial cells and activating a precursor form of urokinase in blood comprising contacting said inactive urokinase in blood with a composition comprising a soluble form of urokinase receptor biocompatibly coupled to a red blood cell carrier.

9. A method for increasing pulmonary uptake of tissue plasminogen activator which comprises crosslinking of biotinylated tissue plasminogen activator to a biotinylated red blood cell or a biotinylated monoclonal antibody specific for red blood cells via streptavidin and administering said crosslinked tissue plasminogen activator to an animal.